XJPX
5187
Market cap56mUSD
Jul 10, Last price
1,144.00JPY
1D
1.69%
1Q
-4.90%
Jan 2017
19.54%
IPO
133.47%
Name
Create Medic Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Create Medic Co., Ltd. engages in the research, manufacturing, and sale of medical appliances in Japan, China, Vietnam, and internationally. The company offers urology products, including all silicone foley, antibacterial foley, hematuria, tieman, suprapubic, and nephrostomy balloon catheters, as well as self-catheterization set, all silicone self-catheter for replacement, pure-cath, nephrostomy kit, cystostomy set, and all silicone malecot catheter; and gastroenterology products, such as all silicone ileus, stomach, and sengstaken blakemore tubes, as well as transanal ileus decompression tube set. It also provides PEG products comprising PEG kit pull-method, with loop fixture, and bumper type, as well as CLINY introducer PEG kit, loop fixture II, all silicone gastrostomy balloon catheter for replacement, balloon button set, facil button for replacement, gastrostomy replacement catheter set, all silicone PEG J catheter, and transgastric jejunal balloon tube and guidewire set; surgery products, which include PTC drainage tube, PTCD kit, cholangio-entero tube, and internal external drainage catheter for PTCD; all silicone endotracheal and tracheostomy tubes and micro catheter; and OEM products. The company was formerly known as NASK Co., Ltd. and changed its name to Create Medic Co., Ltd. in July 1977. Create Medic Co., Ltd. was incorporated in 1974 and is headquartered in Yokohama, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||